Blog
RSS FeedPosted by Michael Wonder on 20 May 2021
Patients with rare blood disorders to receive new treatment option, says NICE
20 May 2021 - Hundreds of people with two rare blood disorders will soon have access to a new treatment regimen ...
Posted by Michael Wonder on 14 May 2021
NICE says final ‘no’ to BMS’ Zeposia for multiple sclerosis
14 May 2021 - NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a ...
Posted by Michael Wonder on 14 May 2021
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
14 May 2021 - NICE recommends pembrolizumab for colorectal cancer patients with rare mutations. ...
Posted by Michael Wonder on 12 May 2021
NICE rejects Pfizer’s rare heart disease treatment Vyndaqel
12 May 2021 - Pfizer’s Vyndaqel has been rejected by NICE as a treatment for the rare heart condition transthyretin ...
Posted by Michael Wonder on 07 May 2021
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy
7 May 2021 - NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or ...
Posted by Michael Wonder on 28 Apr 2021
Thousands with high cholesterol set to benefit from new treatment on the NHS
28 April 2021 - Thousands of people with high cholesterol will soon have access to a new treatment option on the ...
Posted by Michael Wonder on 22 Apr 2021
NICE recommends new treatment for rare blood disorder
22 April 2021 - Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft ...
Posted by Michael Wonder on 21 Apr 2021
Novartis’ MS therapy Kesimpta wins NICE backing
21 April 2021 - Novartis’ Kesimpta has been recommended by NICE for the treatment of relapsing-remitting multiple sclerosis in adult ...
Posted by Michael Wonder on 21 Apr 2021
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia
20 April 2021 - Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated ...
Posted by Michael Wonder on 20 Apr 2021
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer
20 April 2021 - NICE has today published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund for ...
Posted by Michael Wonder on 15 Apr 2021
NICE publishes draft guidance on new use for fenfluramine hydrochloride
15 April 2021 - The Department of Health and Social Care has asked NICE to produce guidance on using fenfluramine hydrochloride ...
Posted by Michael Wonder on 15 Apr 2021
Alexion's pricey Ultomiris wins backing from England's cost watchdogs thanks to confidential discount
15 April 2021 - Alexion has added a nice piece to Ultomiris’ growth potential ahead of its planned merger with ...
Posted by Michael Wonder on 08 Apr 2021
NICE publishes guidance on nivolumab - ipilumumab combo
8 April 2021 - The Department of Health and Social Care has asked NICE to produce guidance on using nivolumab with ...
Posted by Michael Wonder on 06 Apr 2021
NICE backs restricted use of Ondexxya
6 April 2021 - NHS cost regulators have backed funding for Alexion's Ondexxya (andexanet alfa) to reverse anti-coagulation of the ...
Posted by Michael Wonder on 31 Mar 2021
NICE recommends Sobi’s Kineret for first-line use in Still’s disease
31 March 2021 - NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis in people aged eight months ...